Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AMGEN INC. · Firm: TODD STRATEGY GROUP
Cardiovascular disease awareness and treatment. Bone disease awareness and treatment. Implementation of Inflation Reduction Act. Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MCKESSON CORPORATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Source: Senate LDA
| AMGEN, INC. |
| 2 |
| 2026 |
| ASTELLAS PHARMA US, INC. | 2 | 2026 |
| ASTRAZENECA PHARMACEUTICALS LP | 2 | 2026 |
| COMPASS PATHWAYS INC. | 2 | 2026 |
| ELI LILLY AND COMPANY | 2 | 2026 |
| FOX CORPORATION | 2 | 2026 |
| GENENTECH INC | 2 | 2026 |
| JOHNSON & JOHNSON SERVICES, INC. | 2 | 2026 |
| MCKESSON CORPORATION | 2 | 2026 |
| NOVARTIS, INC. | 2 | 2026 |
| NOVO NORDISK, INC. | 2 | 2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2 | 2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 2 | 2026 |
| THE COALITION FOR 21ST CENTURY MEDICINE | 2 | 2026 |
| BAYER CORPORATION | 1 | 2026 |
| BRISTOL-MYERS SQUIBB COMPANY | 1 | 2026 |
| GILEAD SCIENCES, INC. | 1 | 2026 |
| NCTA - THE INTERNET & TELEVISION ASSOCIATION | 1 | 2026 |
| PMI US CORPORATE SERVICES INC. | 1 | 2026 |
| U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER | 1 | 2026 |
H.R.1: One Big Beautiful Bill Act (Public Law 119-21). Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. Center for Medicare and Medicaid Innovation (CMMI) policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. IPAY and Maximum Fair Prices policy issues. Medicaid rebate policy issues. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. IRA price negotiation expansion policy issues.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Women's health and menopause. Issues related to P.L.119-21 (H.R. 1): One Big Beautiful Bill Act. Eye screening and access.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: TODD STRATEGY GROUP
CMMI GENEROUS Demo. Most Favored Nation (MFN). Implementation of the Inflation Reduction Act (IRA) including orphan drug exclusion. Issues related to the Medicare title in Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA). Issues relating to Medicare Parts B and D. Medicare Drug Price Negotiation Program. PBM Reform. 340B Rebate Model Pilot Program. H.R.9599: The SECURE 340B Act. Implementation of Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: TODD STRATEGY GROUP
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Medicare Part B. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues. H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025. Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. Medicaid rebate policy issues.
Maintaining Investments in New Innovation Act
Client: AMGEN INC. · Firm: TODD STRATEGY GROUP
Drug pricing and patient affordability. Issues related to 340B. Biosimilars reimbursement and regulatory standards. Issues related to Supply Chain. H.R.1672: Maintaining Investments in New Innovation (MINI) Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
H.R.3160/S.1553: Promoting and Respecting Economically Viable American Innovation (PREVAIL) Act.
Clinical Trial Modernization Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TODD STRATEGY GROUP
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TODD STRATEGY GROUP
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: TODD STRATEGY GROUP
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Copyright and content carriage issues. Retransmission consent. H.R.4312: SCORE Act. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues. Private lending regulations.
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Community Health Center Drug Pricing Protection Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: TODD STRATEGY GROUP
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
National Defense Authorization Act for Fiscal Year 2027
Client: AMGEN INC. · Firm: TODD STRATEGY GROUP
Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027.
Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight. Accelerated Approval. Breast Cancer Research. Supply Chain Integrity and Traceability. PBM Reform. Coverage of Accelerated Approval Products. Drug Benefit Design. Orphan Drug Issues. S. 1682/H.R.946: ORPHAN Cures Act. Reimbursement and Coverage of Innovative Products. Lower Costs, More Transparency Act. Lower Costs, More Cures Act. Patient Cost-Sharing. Step Therapy. Value-based Contracting and Communications. User fee policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Drug importation policy issues. Competition policy issues. Drug shortages policy issues. IRA price negotiation expansion policy issues. Rare Pediatric Disease Priority Review Voucher program policies. SUSTAIN RFI/discussion draft. Most Favored Nation (MFN) policy. Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Utilization management policies.
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
CMMI GENEROUS Demo. Most Favored Nation (MFN). Implementation of the Inflation Reduction Act (IRA) including orphan drug exclusion. Issues related to the Medicare title in Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA). Issues relating to Medicare Parts B and D. Medicare Drug Price Negotiation Program. PBM Reform. 340B Rebate Model Pilot Program. H.R.9599: The SECURE 340B Act. Implementation of Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
H.R.3160/S.1553: Promoting and Respecting Economically Viable American Innovation (PREVAIL) Act.
Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight. Accelerated Approval. Breast Cancer Research. Supply Chain Integrity and Traceability. PBM Reform. Coverage of Accelerated Approval Products. Drug Benefit Design. Orphan Drug Issues. S. 1682/H.R.946: ORPHAN Cures Act. Reimbursement and Coverage of Innovative Products. Lower Costs, More Transparency Act. Lower Costs, More Cures Act. Patient Cost-Sharing. Step Therapy. Value-based Contracting and Communications. User fee policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Drug importation policy issues. Competition policy issues. Drug shortages policy issues. IRA price negotiation expansion policy issues. Rare Pediatric Disease Priority Review Voucher program policies. SUSTAIN RFI/discussion draft. Most Favored Nation (MFN) policy. Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Utilization management policies.
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027.
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Clinical Trial Modernization Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation.
S.864: HELP Copays Act. IRA Implementation. 340B. Heart Recovery Awareness Day. Obesity treatments. MFN. CMS Outpatient Prospective Payment System rule. Peripheral artery disease (PAD). PBM and Insurer Reforms. Stroke care.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864: HELP Copays Act. General Medicare and Medicaid Issues.
340B Program. Home Infusion for Part B Products. S.864: HELP Copays Act. Medicare Reimbursement for New Technologies.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Supply Chain. 340B Issues. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MENARINI GROUP via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General discussions around Medicare/Medicaid. Implementation of IRA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Health insurance accessibility. Artificial Intelligence in health care.
Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access. CMS National Coverage Determination on Alzheimer's disease. Implementation of the Inflation Reduction Act.
Drug pricing, coverage, value, access and quality. Prescription drug approval. Drug importation. 340 B. Intellectual property. Pharmaceutical supply chain issues and shortages. Transparency. Issues related to intellectual property protection and market access within current trade negotiations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
IP and Bayh-Dole Act.
Implementation of the Inflation Reduction Act. PSA screening bills. Health care transparency.
Medicare Part D.
Women's health and menopause. Issues related to P.L.119-21 (H.R. 1): One Big Beautiful Bill Act. Eye screening and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOX CORPORATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Copyright and content carriage issues. Retransmission consent. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues. College sports media rights. First Amendment issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Implementation of Inflation Reduction Act. Health care supply chain. Treat and Reduce Obesity Act.
Pharmacy Benefit Manager Reform. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COMPASS PATHWAYS INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General education on Compass Pathways. Mental health and PTSD. Psychedelic medicines.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AMERICAN SOCIETY OF NEPHROLOGY via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Kidney transplantation policy. Officer of Kidney Health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA PHARMACEUTICALS LP via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Pharmaceutical tariffs.
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Issues related to the development of novel therapies including cell therapy and antibody drug conjugates (ADCs). Issues related to most-favored nations drug pricing proposals. FDA modernization policy. BIOSECURE Act implementation. Value-based payment arrangements.
AMGEN INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Issues related to tariffs.
H.R.3160/S.1553: Promoting and Respecting Economically Viable American Innovation (PREVAIL) Act.
Cardiovascular disease awareness and treatment. Bone disease awareness and treatment. Implementation of Inflation Reduction Act. Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
SUNBOUND HOMES via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General discussions around Medicare and Medicaid. Long term care issues. AI in healthcare. Data privacy and security.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PFIZER INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification. FDA User Fee Agreements: 2027 PDUFA Cycle. 340B Program Reform. Inflation Reduction Act (IRA). Prior Authorization. Step Therapy Practices. FDA Modernization and Reforms. Drug Pricing. PBM Reform. Vaccine Access and Coverage.
Medicare/Medicaid Issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Domestic and global drug pricing proposals. International trade and protection of intellectual property. Global supply chain issues. Proposals to expand access to HIV treatment and prevention therapies. Coverage and reimbursement policy for Hepatitis C, HIV and cancer. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. 340B program reforms and changes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy.
Biosimilars reimbursement issues.
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
BIOGEN, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
IRA implementation. Issues related to drug pricing. 340B Program. Supply Chain. Issues related to patient affordability and access including copay and coverage reform. Issues related to PBM reform. PDUFA, drug reviews, approval pathways, PPRV Program, clinical trials. Issues related to rare diseases, including the Orphan Drug and ORPHAN CURES Act, rare disease research and screening, and patient access to therapies.
Issues related to Alzheimer's disease and dementia, including screening, diagnosis, and care. Issues related to postpartum depression screening, detection, and education. Issues related to ALS, lupus, and kidney disease policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE COALITION FOR 21ST CENTURY MEDICINE via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Medicare coverage and reimbursement for diagnostics. Prior Authorization for Medicare Advantage.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Issues related to tariff and trade policy.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Patient assistance program policy issues.
Tariff policy issues.
H.R.1: One Big Beautiful Bill Act (Public Law 119-21). Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. Center for Medicare and Medicaid Innovation (CMMI) policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. IPAY and Maximum Fair Prices policy issues. Medicaid rebate policy issues. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. IRA price negotiation expansion policy issues.
NOVARTIS, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight. Accelerated Approval. Breast Cancer Research. Supply Chain Integrity and Traceability. PBM Reform. Coverage of Accelerated Approval Products. Drug Benefit Design. Orphan Drug Issues. S. 1682/H.R.946: ORPHAN Cures Act. Reimbursement and Coverage of Innovative Products. Lower Costs, More Transparency Act. Lower Costs, More Cures Act. Patient Cost-Sharing. Step Therapy. Value-based Contracting and Communications. User fee policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Drug importation policy issues. Competition policy issues. Drug shortages policy issues. IRA price negotiation expansion policy issues. Rare Pediatric Disease Priority Review Voucher program policies. SUSTAIN RFI/discussion draft. Most Favored Nation (MFN) policy. Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Utilization management policies.
Outbound investment issues.
NCTA - THE INTERNET & TELEVISION ASSOCIATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
College Athletics/Sports Media. Broadband Deployment. BEAD and Rural Broadband funding. Spectrum/wireless policy. Affordability, Lifeline, Consumer protection. Network security/supply chain. Online safety. Video programming.
Filing targets: HOUSE OF REPRESENTATIVES
JOHNSON & JOHNSON SERVICES, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
VA/military affairs.
S.864: HELP Copays Act. IRA Implementation. 340B. Heart Recovery Awareness Day. Obesity treatments. MFN. CMS Outpatient Prospective Payment System rule. Peripheral artery disease (PAD). PBM and Insurer Reforms. Stroke care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Tax policy.
Tariffs.
CMMI models. IRA implementation.
IP protection.
PMI US CORPORATE SERVICES INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Discussions concerning federal funding related to the Centers for Disease Control and Prevention.
Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to tobacco harm reduction. Discussions related to enforcement of illicit tobacco products, including importation of counterfeit products. Discussions related to user fees for tobacco and electronic nicotine delivery system products. Discussions related to efforts to prevent youth access to tobacco products. Provisions related to FDA regulation of tobacco.
GENENTECH, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Appropriations and budget issues including: LHHS-Ed, Ag-FDA, and HHS program funding. Reconciliation and deficit reduction.
Issues related to IP and patent policy reform. Issues related to FDA regulation and drug development including PDUFA and biosimilars.
Issues related to drug pricing and coverage. Medicare and Medicaid payment issues. Implementation of the IRA. 340B Program.
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Issues related to the implementation of the Inflation Reduction Act. Home infusion policy. Issues related to MFN drug pricing.
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94). Drug Pricing. FY2026 Labor HHS appropriations. Genetically targeted technologies. Policies related to medical innovation.
Issues relating to supply chain tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MENARINI GROUP via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General discussions around Medicare/Medicaid. Implementation of IRA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Issues related to tariff and trade policy.
Filing targets: HOUSE OF REPRESENTATIVES
SUNBOUND HOMES via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General discussions around Medicare and Medicaid. Implementation of CRUSH initiative. Long term care issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864: HELP Copays Act. General Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Issues related to tariff and trade policy.
Issues related to tariff and trade policy. International Supply Chain.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
NOVO NORDISK INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MCKESSON CORPORATION via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
JOHNSON & JOHNSON SERVICES, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FOX CORPORATION via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Copyright and content carriage issues. Retransmission consent. H.R.4312: SCORE Act. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues. Private lending regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMPASS PATHWAYS INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General education on Compass Pharmaceuticals. Mental health and PTSD.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
THE COALITION FOR 21ST CENTURY MEDICINE via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Medicare coverage and reimbursement for diagnostics. FDA LDT Regulation. Prior Authorization for Medicare Advantage. Medicare contractor reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOGEN, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program.
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA PHARMACEUTICALS LP via TODD STRATEGY GROUP
2026 · second_quarter · Q2
340B Program. Home Infusion for Part B Products. S.864: HELP Copays Act. Medicare Reimbursement for New Technologies.
Pediatric Priority Review Voucher Program. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Global supply chain and investment issues. Prescription drug pricing policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ASTELLAS PHARMA US, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Women's health.
Prescription drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Prescription Drug Pricing Policy. Supply Chain Issues.
Prescription drug pricing policy.
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN SOCIETY OF NEPHROLOGY via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Kidney transplantation policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Tariffs.
Supply Chain. 340B Issues. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
MENARINI GROUP via TODD STRATEGY GROUP
2026 · second_quarter · RR
General discussions around Medicare/Medicaid. Implementation of IRA.
SUNBOUND HOMES via TODD STRATEGY GROUP
2026 · first_quarter · RR
Waste, fraud, and abuse.
ELI LILLY AND COMPANY via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Alzheimer's Disease. Anti Obesity Medication.
Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. Issues related to drug compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Issues related to tariff and trade policy.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
BIOGEN, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to tariff and trade policy. International Supply Chain.
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program.
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CMMI GENEROUS Demo. Most Favored Nation (MFN). Implementation of the Inflation Reduction Act (IRA) including orphan drug exclusion. Issues related to the Medicare title in Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA). Issues relating to Medicare Parts B and D. Medicare Drug Price Negotiation Program. PBM Reform. 340B Rebate Model Pilot Program. H.R.9599: The SECURE 340B Act. Implementation of Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Drug pricing and patient affordability. Issues related to 340B. Biosimilars reimbursement and regulatory standards. Issues related to Supply Chain. H.R.1672: Maintaining Investments in New Innovation (MINI) Act.
PBM reform.
Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Biopharmaceutical innovation policy issues. Biosimilar approval and reimbursement policy issues.
User fee issues. Vaccine policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Most Favored Nation (MFN) policy issues. Drug importation policy issues. FDA policy issues. Competition policy issues. Orphan Drug Act policy issues. Antimicrobial resistance policy issues. Supply chain policy issues. 340B drug discount program rebate and policy issues. Drug shortages policy issues . Executive Order 14297: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Executive Order 14273: Lowering Drug Prices by Once Again Putting Americans First. Biopharmaceutical innovation policy issues. Pricing and reimbursement policy issues. Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues.
Presidents Budget Fiscal Year 2027. Government funding policy issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medicare Part B. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues. H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025. Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. Medicaid rebate policy issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Drug pricing. 340B. PBM reform. Copay assistance. GRAS reform. Small molecule drug innovation. Womens health. Biotech investment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Discussions concerning the FY 2026 appropriations bills.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to antimicrobial resistance and infectious disease. Issues related to public health preparedness including the SNS and supply chain. Issues related to awareness about diabetic eye diseases. Issues related to privacy and consumer information. Medical research data.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tariff and trade policy. International Supply Chain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE